Media coverage about Exactech (NASDAQ:EXAC) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.2780898001385 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Exactech (NASDAQ EXAC) opened at $50.45 on Friday. Exactech has a 1 year low of $23.30 and a 1 year high of $50.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. The firm has a market cap of $724.77, a price-to-earnings ratio of 5,045.00, a P/E/G ratio of 3.65 and a beta of 1.02.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.22%. The firm had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. equities analysts anticipate that Exactech will post 1.29 earnings per share for the current year.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech and related companies.